• Comment on PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia

      Perrotti, D; Agarwal, A; Lucas, Claire; Narla, g; Nevanini, p; Odero, m; Ruvolo, p; Verrills, n; University of Maryland; Imperial College London; Oregon Health and Science University; University of Chester; University of Michigan; University of Southern California; University of Navarra; MD Anderson Cancer Center; University of Newcastle (American Association for the Advancement of Science, 2019-07-17)
      LB100 does not sensitize CML stem cells to tyrosine kinase inhibitor–induced apoptosis.